In SSc patients, ibrutinib, a BTK inhibitor, has been found to reduce the production of pro-inflammatory cytokines and autoantibodies by peripheral B cells, while not affecting their IL-10 secretion (110). This evidence concerns the gene IL10 and systemic sclerosis.